Company news

Percheron Therapeutics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Update - Proposed issue of securities - PER

November 3, 2026

Update - Proposed issue of securities - PER

November 3, 2026

Update - Proposed issue of securities - PER

November 3, 2026

Prospectus - Placement options and JLM options

November 3, 2026

FDA Clearance for Vanderbilt Health Clinical Trial in AML

November 1, 2026

Listing Rule waiver to allow quotation of PERAQ options

October 29, 2026

Completion of HMBD-002 Drug Product Manufacture

October 22, 2026

Quarterly Activities Report and Appendix 4C

October 19, 2026

Quarterly Activities Report and Appendix 4C

October 19, 2026

Photosoft & Novel Immunotherapy Collab Partnership

October 19, 2026

PER: Percheron and Invion Explore Cancer Combination Therapy

October 19, 2026

Change of Director's Interest Notice

October 14, 2026

Notice under S708A

October 14, 2026

Application for quotation of securities - PER

October 13, 2026

Application for quotation of securities - PER

October 13, 2026

Change of Director's Interest Notice

October 7, 2026

Notification regarding unquoted securities - PER

October 7, 2026

Results of Annual General Meeting

October 7, 2026

Annual General Meeting - Management Presentation

October 6, 2026

Annual General Meeting - Chair Address

October 6, 2026

Proposed issue of securities - PER

October 5, 2026

Final Director's Interest Notice

October 4, 2026

Initial Director's Interest Notice

October 4, 2026

Dr Michael Baker Commences as CEO and MD

October 4, 2026

Notice under S708A

September 7, 2026

Application for quotation of securities - PER

September 6, 2026

2026 Notice of Annual General Meeting

September 6, 2026

Percheron Therapeutics Limited Corporate Presentation

August 31, 2026

Percheron raises $2.3m to fully fund clinical trial in AML

August 31, 2026

Proposed issue of securities - PER

August 31, 2026

Proposed issue of securities - PER

August 31, 2026

Proposed issue of securities - PER

August 31, 2026

Initial Director's Interest Notice

August 31, 2026

Transitional appointment of Executive Director

August 31, 2026

Change of Director's Interest Notice

August 31, 2026

Notification of cessation of securities - PER

August 31, 2026

Percheron receives $0.70m R&D Tax Incentive Rebate

August 30, 2026

Trading Halt

August 27, 2026

Vanderbilt Health to conduct clinical trial of HMBD-002

August 27, 2026

Appendix 4E and Annual Report

August 19, 2026

Appendix 4G and Corporate Governance Statement

August 18, 2026

Appendix 4E and Annual Report

August 18, 2026

Application for quotation of securities - PER

August 14, 2026

Notice of date of AGM and other relevant dates

August 11, 2026

Percheron Therapeutics Announces CEO Succession

August 9, 2026

Quarterly Activities Report and Appendix 4C

July 30, 2026

Results of Entitlement Offer

April 14, 2026

Prospectus - Non-renounceable Entitlement Offer

March 15, 2026

Non-renounceable Entitlement Offer

March 15, 2026

Half Yearly Report and Accounts

February 26, 2026

Older news releases →

Decks

The 5 newest of 17 decks. Every deck is listed under its year.